cross-posted from: https://mander.xyz/post/11304633

Ozempic maker Novo Nordisk facing pressure as study finds $1,000 appetite suppressant can be made for just $5

  • 0xvalentin@lemmy.sdf.org
    link
    fedilink
    English
    arrow-up
    2
    arrow-down
    3
    ·
    9 months ago

    I read the article and I don’t think it factors in the upfront cost of R&D, Compliance, etc, so that’s basically a fantasy number.

    • Banzai51@midwest.social
      link
      fedilink
      English
      arrow-up
      3
      ·
      9 months ago

      Those are the costs of doing business, and can be greatly exaggerated. And other counties produce profitable drugs even with price restrictions. We’re so accustomed to price gouging, that we don’t recognize it.

    • seriousconsideration@lemmy.dbzer0.com
      link
      fedilink
      English
      arrow-up
      3
      ·
      edit-2
      9 months ago

      You’re probably right. It’s more than likely the cost per dose. Which is also what the $1000 figure represents.

      The Vermont independent (Bernie) called on Novo Nordisk to lower the list price of Ozempic to $155 a month or less, in line with what it charges in other countries.

      Somehow they can justify selling it for $155 a dose (per month?) in other countries while still making a profit above the overhead and compliance costs.